MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
• MicroRNAs (miRNAs) play a crucial role in cancer development and progression.
• Understanding the molecular mechanisms of CRC, including miRNA involvement, is vital for new therapeutic strategies.

Purpose of the Study:

• To investigate the role of the miR-320 family in colorectal cancer.
• To identify novel molecular targets regulated by miR-320 in CRC.
• To explore the therapeutic potential of targeting the miR-320 pathway in CRC.

Main Methods:

• Analysis of miR-320 family expression in CRC tissues and cell lines.
• Lentiviral-mediated re-expression of miR-320c in CRC cells and in vivo tumor models.
• Global gene expression analysis and in silico prediction to identify miR-320 targets.
• Biochemical assays and functional validation of target genes (SOX4, FOXM1, FOXQ1).
• Correlation analysis with patient data from The Cancer Genome Atlas (TCGA).

Main Results:

• The miR-320 family is frequently downregulated in primary CRC tissues and cell lines.
• Re-expression of miR-320c suppressed CRC cell growth, migration, and tumor formation in mice.
• miR-320c sensitized CRC cells to 5-Fluorouracil (5-FU) chemotherapy.
• SOX4, FOXM1, and FOXQ1 were identified and validated as direct targets of the miR-320 family.
• Elevated expression of SOX4, FOXM1, and FOXQ1 correlated with poor disease-free survival in CRC patients.

Conclusions:

• The miR-320 family, particularly miR-320c, acts as a tumor suppressor in colorectal cancer.
• The miR-320/SOX4/FOXM1/FOXQ1 axis is a novel pathway involved in CRC development and progression.
• Targeting this axis represents a potential therapeutic strategy for colorectal cancer.